Trédan O - Search Results

1

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

Patel KJ, Trédan O, Tannock IF. Patel KJ, et al. Among authors: tredan o. Cancer Chemother Pharmacol. 2013 Jul;72(1):127-38. doi: 10.1007/s00280-013-2176-z. Epub 2013 May 17. Cancer Chemother Pharmacol. 2013. PMID: 23680920

2

Drug resistance and the solid tumor microenvironment.

Trédan O, Galmarini CM, Patel K, Tannock IF. Trédan O, et al. J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54. doi: 10.1093/jnci/djm135. Epub 2007 Sep 25. J Natl Cancer Inst. 2007. PMID: 17895480 Review.

3

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

Trédan O, Garbens AB, Lalani AS, Tannock IF. Trédan O, et al. Cancer Res. 2009 Feb 1;69(3):940-7. doi: 10.1158/0008-5472.CAN-08-0676. Epub 2009 Jan 27. Cancer Res. 2009. PMID: 19176397

4

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies.

Cornet S, Mathé D, Chettab K, Evesque A, Matera EL, Trédan O, Dumontet C. Cornet S, et al. Among authors: tredan o. Mol Cancer Ther. 2016 Jun;15(6):1238-47. doi: 10.1158/1535-7163.MCT-15-0759. Epub 2016 Mar 17. Mol Cancer Ther. 2016. PMID: 26988998

5

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.

6

[Can tumor hypoxia be turned into a chemotherapeutic advantage?].

Trédan O, Grantab R, Dumontet C. Trédan O, et al. Bull Cancer. 2008 May;95(5):528-34. doi: 10.1684/bdc.2008.0637. Bull Cancer. 2008. PMID: 18541517 Free article. Review. French.

7

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

Jobard E, Blanc E, Négrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Trédan O. Jobard E, et al. Among authors: tredan o. Br J Cancer. 2015 Oct 20;113(8):1148-57. doi: 10.1038/bjc.2015.322. Epub 2015 Sep 15. Br J Cancer. 2015. PMID: 26372698 Free PMC article.

8

Concomitant resistance and early-breast cancer: should we change treatment strategies?

Galmarini CM, Tredan O, Galmarini FC. Galmarini CM, et al. Among authors: tredan o. Cancer Metastasis Rev. 2014 Mar;33(1):271-83. doi: 10.1007/s10555-013-9449-1. Cancer Metastasis Rev. 2014. PMID: 24346157 Review.

9

Survivorship in untreated breast cancer patients.

Galmarini CM, Tredan O, Galmarini FC. Galmarini CM, et al. Among authors: tredan o. Med Oncol. 2015 Feb;32(2):466. doi: 10.1007/s12032-014-0466-x. Epub 2015 Jan 15. Med Oncol. 2015. PMID: 25588926 Review.

10

Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.

Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, Vaz Luis I, Charles C, Lemogne C, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Petit T, Dalenc F, Rouanet P, Lemonnier J, Everhard S, Cottu P, Joly F. Licaj I, et al. Among authors: tredan o. Cancer. 2023 Apr 1;129(7):1085-1095. doi: 10.1002/cncr.34643. Epub 2023 Jan 15. Cancer. 2023. PMID: 36642837 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page